M&A Deal Summary |
|
|---|---|
| Date | 2015-12-07 |
| Target | R-Tech Ueno |
| Sector | Life Science |
| Buyer(s) | Sucampo Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Deal Value | 275M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1996 |
| Sector | Life Science |
| Employees | 80 |
| Revenue | 115M USD (2014) |
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of highly specialized medicines. Sucampo has a late-stage pipeline of product candidates in clinical development for orphan disease areas, including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C, a rare progressive genetic disorder. VTS-270 has also been granted breakthrough therapy designation in the U.S. Sucampo has an exclusive option for the North American rights to CPP-1X/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. The company has two marketed products – AMITIZA and RESCULA.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 2 |
| Country: Japan M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-04-03 |
Vtesse
Gaithersburg, Maryland, United States Vtesse, Inc. is a disease company focused on developing drugs for patients suffering from diseases that are under-served. Vtesse is based in Gaithersburg, Maryland. |
Buy | $200M |
